This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
25 Jan 2022

Sai Life Sciences commences recruitment of 100+ scientists for its fast-growing drug discovery business

Sai Life Sciences today commenced recruitment for 100+ scientific positions across medicinal chemistry and biology to bolster the company’s growth plans of achieving scale, scope and speed in its Discovery business. All positions will be based at the company’s Integrated Research & Development campus in Hyderabad, India.

Sai Life Sciences commences recruitment of 100+ scientists for its fast-growing drug discovery business

Sai Life Sciences today commenced recruitment for 100+ scientific positions across medicinal chemistry and biology to bolster the company’s growth plans of achieving scale, scope and speed in its Discovery business. All positions will be based at the company’s Integrated Research & Development campus in Hyderabad, India.

Making the announcement, Krishna Kanumuri, CEO & MD, Sai Life Sciences said, “These are exciting times for all of us at Sai Life Sciences! The investments we have made as part of Sai Nxt are finding resonance with biotech and pharmaceutical innovators globally, especially as our global delivery model is bringing value to our customers through an optimal blend of talent, speed, and cost efficiency.”

The present recruitment drive is aimed at increasing capacity in India to meet the growing demand for the company’s discovery services. In recent months, the company has doubled its headcount at both its Boston and Manchester sites.

Sai Life Sciences is currently at the halfway mark of its organizational transformative initiative, Sai Nxt. Backed by an investment commitment of US$150M and envisaged as a 4-year program from 2019 to 2023, it aims to drive transformation across three core areas: (1) People & culture (2) Processes & automation (3) Infrastructure & scientific capabilities. So far, the company has already invested US$100M, enabling an upsurge in the company’s capabilities, augmenting its standing as a global CRO-CDMO offering cutting edge solutions to innovator pharma and biotech companies.

The company is looking to on-board top-notch global scientific talent with M.Sc./ Ph.D / Post Doctorates in synthetic organic / analytical chemistry from reputed academic institutions, and experience in global pharma R&D of up to 20 years, for various roles across levels in medicinal chemistry, biology, DMPK and toxicology.

Mentioned Companies
Sai Life Sciences
View company profile